Aducanumab Enrolling by Invitation Phase 3 Trials for Alzheimer's Disease (AD) Treatment

IndicationsStatusPurposePhase
Enrolling by InvitationTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT04241068A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205